One example of the aforementioned dichotomy is Cutera Inc. versus Vapotherm Inc. (Figure 1). The former specializes in devices used in cosmetic surgery and has declined 48% from February 28 to May 19. In contrast, Vapotherm, which specializes in products used to treat respiratory distress, has seen a 176% return over the same period. Vapotherm’s oxygen controller was awarded ‘breakthrough device’ status by the FDA on April 9.
Figure 1. Performance of Vapotherm, Inc. and Cutera, Inc. alongside the S&P 500 Total Return and the Health Care Sector SPDR (XLV)
Source: S&P Global Market Intelligence Quantamental Research. Data as of May 20, 2020.
Please access the complete list of Quantamental Research Briefs for the latest on COVID-19’s impact.
Explore S&P Global MarketplaceClick here
Quantamental Research Brief: Finding the Healthy Stocks in Health Care During Lockdown
Quantamental Research Brief: No More Walks in the (Office) Park: Tying Foot Traffic Data to REITs
Quantamental Research Brief: Do Markets Yearn for the Dog Days of Summer? COVID, Climate, and Consternation